MTOR and neoplasm: Treatment with the PI3K inhibitor (LY294002) resulted in significant reduction in p‐AKT (T308) and p‐S6 (S240/244) in mGICPten−/−;p53−/−‐CM and GL261‐conditioned microglia (Figs 2H and I, and EV1A and B) but not in BMDM (Fig EV1D–F), thereby confirming activation of mTOR signalling via PI3K/AKT in tumour‐conditioned microglia.